Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Nivolumab plus Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer
jRCT2080225201Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Nivolumab + Docetaxel + Prednisone with Placebo + Docetaxel + Prednisone (2 arms). Started May 2020; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2080225201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225201.